Physician‑executive with end‑to‑end experience across patent‑stage ideation, prototype and preclinical development, first‑in‑human and pivotal trials, PMA submission, post‑approval evidence, and commercialization — grounded in active complex intervention and long‑standing Harvard Medical School faculty work.
Pivotal → PMA → IDE strategy, FDA negotiation, enterprise risk oversight, investor/board communications, launch readiness, and post‑market evidence strategy.
Complex coronary & structural intervention, teaching and mentorship, and a sustained publication record with trial and outcomes rigor.
Reflections on career development, institutional responsibility, and sustaining excellence across clinical and executive roles.
A discussion on sustaining growth across clinical, academic, and executive domains—covering mentorship, disciplined curiosity, and the transition from procedural mastery to strategic leadership.
Watch on YouTube →Dr. Pinto has served on the faculty of Harvard Medical School for more than two decades, with a career focused on complex interventional cardiology, translational device development, and clinical outcomes research.
He maintains an active procedural practice across coronary, peripheral, and structural heart disease, including high-risk PCI, large-bore access strategy, first-in-human device procedures, and translational animal studies supporting early innovation.
He has also taught first-year cardiac physiology at Harvard Medical School, contributing to foundational medical education while continuing full-time interventional practice.
Leadership roles within Harvard-affiliated programs have included Chief Resident, Fellowship Director, Director of the Coronary Care Unit, and Chief, Interventional Cardiology Section.
Clinical Topics & Key Questions
Core clinical domains, practical resources, and concise answers to the questions that most often determine referral strategy, procedural risk, and follow‑up planning.
Selected guides on structural heart disease, coronary disease, and procedural therapies.
Overview of aortic, mitral, and tricuspid valve disease, symptoms, evaluation, and treatment pathways.
Read guide →How coronary plaque causes angina and heart attacks, and how we diagnose and treat CAD.
Read guide →Transcatheter replacement for diseased aortic valves — candidacy, procedure, and follow-up.
Read guide →Browse all clinical guides and links in one place.
View all →The aortic valve sits immediately adjacent to the heart’s electrical conduction system (shown in green). When a transcatheter valve is expanded, it can compress this delicate tissue and disrupt conduction.
In some cases, the disturbance is temporary and resolves. In others, the recovery is uncertain or the block is persistent and requires pacemaker implantation.
Key point: Anatomical variation and deployment depth influence risk — making conduction outcomes both a technical and a systems endpoint.
Trials do more than establish efficacy and safety — they define patient selection, procedural technique, complication management, and follow‑up strategy. High‑quality trials reduce variability and enable scalable adoption.
Post‑approval studies and real‑world database research answer durability, generalizability, and implementation questions that emerge after broader adoption — and can materially influence labeling, guidelines, and market confidence.
Enterprise device lifecycle leadership including pivotal trial execution, regulatory strategy, successful PMA and IDE submissions, post‑approval study oversight, and commercialization alignment.
Lifecycle leadership. I have led cardiovascular device programs from early innovation through regulatory approval and post‑market evidence generation — including patent‑stage concept work, prototype refinement, preclinical and animal studies, first‑in‑human and early feasibility efforts, pivotal registrational trials, PMA submission, and post‑approval studies.
Enterprise impact. I have taken programs from completion of pivotal trials through publication and successful PMA submission, negotiated with FDA to develop subsequent IDE pathways, presented clinical and regulatory strategy to boards and prospective investors, contributed to commercial launch planning (professional education and training), and testified before the FTC in merger‑related proceedings. I have also initiated and directly overseen clinical operations for a 1,000‑patient multicenter trial.
Proof points in peer‑reviewed evidence and high-stakes milestone discussions—selected for relevance to adoption and governance.
Milestones
Selected discussions where evidence, adoption constraints, and procedural strategy converge.
Selected discussions where data, adoption, and clinical practice converge — with emphasis on structural heart innovation, regulatory pathways, and real‑world implementation.
A concise procedural visualization supporting device understanding, education, and implementation framing.
A pivotal discussion of the first large prospective AR experience — moving beyond feasibility into adoption, durability, conduction management, and regulatory implications.
How non‑calcified anatomy changes anchoring assumptions, how conduction outcomes shape patient selection, and why trial design matters for real‑world implementation.
On aligning innovation with evidentiary rigor, operating under scrutiny, and building influence across academic, regulatory, and industry domains.
Selected Talks
A small set of signature clips—chosen to show how complex clinical and translational decisions are communicated clearly.
A capital-markets oriented discussion on how evidence strategy, procedural reality, and systems-of-care shape durable adoption in cardiovascular innovation.
Watch on YouTube →Reflections on disciplined growth across clinical, academic, and leadership domains—mentorship, decision-making, and sustaining excellence over time.
Watch on YouTube →
Technical principles for safe large-bore access, closure planning, and mitigation of vascular complications in high-risk structural and mechanical support cases.
Watch →
First‑in‑human clinical results of the Magenta Elevate high‑output MCS pump. Procedures performed by Dr. Pinto; results presented at TCT 2022 and published in 2024.
Watch →Note: videos open in a new tab; embeds are loaded lazily for performance.